Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vascular events associated with alpha interferon therapy.

H Al-Zahrani1, V Gupta, M D Minden

  • 1Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health network, 610 University Avenue, Toronto Ont., Canada, M5G 2M9.

Leukemia & Lymphoma
|April 12, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiovascular events among recipients of hematopoietic stem cell transplantation-A systematic review and meta-analysis.

Bone marrow transplantation·2023
Same author

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.

Leukemia·2020
Same author

Molecular analysis and genotype-phenotype correlation of Diamond-Blackfan anemia.

Clinical genetics·2017
Same author

Aspergillus galactomannan detection in exhaled breath condensate compared to bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in immunocompromised patients.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2017
Same author

Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results.

Leukemia·2017
Same author

CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission.

Blood cancer journal·2017

Alpha Interferon (IFN) therapy can cause severe vascular complications, including Raynaud's phenomena and pulmonary hypertension. Discontinuing IFN and starting immunosuppressive treatment can resolve these adverse reactions.

Area of Science:

  • Oncology
  • Immunology
  • Vascular Medicine

Background:

  • Alpha Interferon (IFN) is a biological agent used in treating various diseases, including chronic myeloid leukemia and malignant melanoma.
  • IFN therapy, while effective, can lead to serious adverse reactions, necessitating careful patient monitoring.

Observation:

  • This study details vasculopathic complications in 13 patients undergoing IFN therapy.
  • Observed vascular manifestations included Raynaud's phenomena, digital ulcerations, gangrene, pulmonary vasculitis, pulmonary hypertension, and thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS).
  • These complications arose after 3 months to 3 years of daily IFN treatment, with 5 patients also receiving hydroxyurea (HU).

Findings:

  • IFN-associated vasculopathic and vasospastic complications were observed in patients with chronic myeloid leukemia and malignant melanoma.

Related Experiment Videos

  • Discontinuation of IFN therapy, coupled with immunosuppressive treatment, led to resolution or halted progression of these vascular reactions.
  • Early diagnosis and immediate cessation of IFN are crucial for managing these severe adverse events.

    • Implications:

    • IFN therapy carries a risk of significant vasculopathic complications that require prompt recognition and management.
    • Understanding the underlying mechanisms of these reactions is vital for improving patient safety during IFN treatment.
    • This highlights the importance of vigilant monitoring for vascular adverse events in patients receiving Alpha Interferon.